<!DOCTYPE html>
<html class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>Pulmonary embolism - Approach | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="description" content="Pulmonary embolism (PE) is a life-threatening condition resulting from dislodged thrombi occluding the pulmonary vasculature; right heart failure and cardiac arrest may ensue if not aggressively treated. Symptoms include chest pain, dyspnoea, and a sense of apprehension. Haemoptysis and syncope a...">
      <!-- Optimize Page Hiding Snippet --> 
      <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="../js/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="../js/414393182248444" async=""></script><script async="" src="../js/fbevents.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/get-loader.js"></script><script type="text/javascript" async="" src="../js/insight.min.js"></script><script type="text/javascript" async="" src="../js/js"></script><script type="text/javascript" async="" src="../js/uwt.js"></script><script type="text/javascript" async="" src="../js/4896.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script>
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': null,
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script>
      <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script>
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/116/management-approach">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/116/management-approach">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/116/management-approach">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/management-approach">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/116/management-approach">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/116/management-approach">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/116/management-approach">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/116/management-approach">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/116/management-approach">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/116/management-approach">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/116/management-approach">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/management-approach">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/116/management-approach">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/116/management-approach">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/116/management-approach">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/116/management-approach">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/116/management-approach">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach">
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script>
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <style></style>
   </head>
   <body class="gpw">
      <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 cc-invisible" style="display: none;">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
      </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-register" class="nav-item">
                        <a href="https://bestpractice.bmj.com/registration" class="nav-link">Create account</a>
                     </li>
                     <li id="globalNav-login" class="nav-item">
                        <a href="https://bestpractice.bmj.com/login" class="nav-link">Log in</a>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            // These are required in completion, see BP-232
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <main id="tmp" class="container tmp tmp-basic main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 116; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/116">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/116">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/116">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>Pulmonary embolism</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 176px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 176px;">
                  <ul id="menus" role="menubar">
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-0">
                           <li><a href="116_overview_summary.html" id="Summary">Summary</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-1">
                           <li><a href="116_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                           <li><a href="116_theory_aetiology.html" id="Aetiology">Aetiology</a></li>
                           <li><a href="116_theory_case_history.html" id="Case history">Case history</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-2">
                           <li><a href="116_diagnosis_recommendations.html" id="Approach">Recommendations</a></li>
                           <li><a href="116_diagnosis_history-exam.html" id="History and exam">History and exam</a></li>
                           <li><a href="116_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                           <li><a href="116_diagnosis_differentials.html" id="Differentials">Differentials</a></li>
                           <li><a href="116_diagnosis_criteria.html" id="Criteria">Criteria</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-3">
                           <li><a href="116_management_recommendations.html" id="Approach" class="active">Recommendations</a></li>
                           <li><a href="116_management_treatment_algorithm.html" id="Treatment algorithm">Treatment algorithm</a></li>
                           <li><a href="116_management_emerging.html" id="Emerging">Emerging</a></li>
                           <li><a href="116_management_prevention.html" id="Prevention">Prevention</a></li>
                           <li><a href="116_management_patient_discussions.html" id="Patient discussions">Patient discussions</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-4">
                           <li><a href="116_follow_up_monitoring.html" id="Monitoring">Monitoring</a></li>
                           <li><a href="116_follow_up_complications.html" id="Complications">Complications</a></li>
                           <li><a href="116_follow_up_prognosis.html" id="Prognosis">Prognosis</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-5">
                           <li><a href="116_resources_guidelines.html" id="Guidelines">Guidelines</a></li>
                           <li><a href="116_resources_images_videos.html" id="Images and videos">Images and videos</a></li>
                           <li><a href="116_resources_references.html" id="References">References</a></li>
                           <li><a href="116_resources_patient_leaflets.html" id="Patient leaflets">Patient leaflets</a></li>
                           <li><a href="116_resources_evidence.html" id="Evidence">Evidence</a></li>
                        </ul>
                     </li>
                     <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
                  </ul>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Approach</h2>
         <div class="card">
            <div class="card-block">
               <section>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Severity of PE is based upon the estimated risk of early death.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                     Considerations include haemodynamic stability (systolic blood pressure [BP] &gt;90 mmHg or systolic BP &lt;90 mmHg) and clinical probability (Wells criteria or Geneva score).
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Haemodynamically unstable patients require urgent primary re-perfusion, anticoagulation, and supportive care. For those at intermediate risk of a poor outcome, anticoagulation and ongoing monitoring is required and rescue re-perfusion should be considered. Those at low risk of a poor outcome can be considered for early discharge or home treatment with appropriate anticoagulation, with careful consideration of the patient’s personal circumstances.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
               </section>
               <section>
                  <h3>Suspected PE with shock or hypotension</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     High-risk patients (presenting with shock or hypotension [i.e., systolic BP &lt;90 mmHg]) require aggressive treatment with primary re-perfusion, anticoagulation, and supportive therapy.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Supportive therapies and empirical anticoagulation (unless contraindicated) should be instituted without delay.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Unfractionated heparin (UFH) may be preferred in this population;
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;however, the choice of anticoagulant may be influenced by patient factors such as presence of cancer, pregnancy, renal function, hepatic function, obesity, and risk of bleeding (e.g., haemodynamic stability, systemic thrombolytic therapy, need for extended anticoagulation). Choice may also depend on physician or patient preference, or recommendations in local guidelines. 
                  </p>
               </section>
               <section>
                  <h3>Supportive therapies</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Local resuscitation protocols should be followed.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Respiratory support
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Supplemental high-concentration oxygen should be administered, targeting oxygen saturations of 94% to 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure).
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop164" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[164]</a> 
                           <span class="citationText" aria-hidden="true">O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(Suppl 1):ii1-90.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/2017-emergency-oxygen-guideline/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/28507176?tool=bestpractice.com
                           </span>
                           </span>
                           &nbsp;
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Intubation and mechanical ventilation may be necessary for patients with severe hypoxaemia/respiratory failure. Mechanical ventilation can lead to hypotension, so BP should be monitored closely.
                        </p>
                        <hr class="fw">
                        <span class="inlineVid">
                        <a href="https://bestpractice.bmj.com/procedural-videos/en-gb/67fc9278-908e-48af-8752-085b1de23b79">
                        <img src="../images/67fc9278-908e-48af-8752-085b1de23b79.jpg" class="pr-3" alt="Tracheal intubation animated demonstration">
                        Tracheal intubation animated demonstration 
                        </a>
                        </span>
                        <hr class="fw">
                        <hr class="fw">
                        <span class="inlineVid">
                        <a href="https://bestpractice.bmj.com/procedural-videos/en-gb/129b1e64-893a-4a65-b198-d27e27f17088">
                        <img src="../images/129b1e64-893a-4a65-b198-d27e27f17088.jpg" class="pr-3" alt="Bag-valve-mask ventilation animated demonstration">
                        Bag-valve-mask ventilation animated demonstration 
                        </a>
                        </span>
                        <hr class="fw">
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Intravenous fluids
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If systolic BP is &lt;90 mmHg, intravenous fluids should be given. Acute right ventricular failure with resulting low systemic output is the leading cause of death in patients with PE.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Studies indicate that aggressive volume expansion is of no benefit, and may even worsen right ventricular function by causing mechanical overstretch, or by reflex mechanisms that depress contractility. However, modest fluid challenge (i.e., 500 mL) may be of benefit in patients with PE, a low cardiac index, and normal BP.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop168" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[168]</a> 
                           <span class="citationText" aria-hidden="true">Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med. 1999 Mar;27(3):540-4.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/10199533?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Vasoactive agents
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If systolic BP is &lt;90 mmHg, vasopressors may be given in parallel with (or while waiting for) pharmacological, surgical, or interventional re-perfusion treatment.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Noradrenaline (norepinephrine) may improve right ventricular function and right ventricular coronary perfusion.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                           However, its use should probably be limited to hypotensive patients.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Dobutamine enhances contractility with an increase in stroke volume and cardiac output. However, its systemic vasodilatory effect can lead to hypotension.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Adrenaline (epinephrine) combines the beneficial properties of noradrenaline (norepinephrine) (vasoconstriction with increased right ventricular perfusion, positive inotropy) and dobutamine (positive inotropy), but without the vasodilatory effects associated with the latter.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop169" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[169]</a> 
                           <span class="citationText" aria-hidden="true">Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest. 1997 Jan;111(1):218-24.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/8996020?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                  </ul>
               </section>
               <section>
                  <h3>Acute phase anticoagulation</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients who present with suspected PE should receive an anticoagulant in the acute phase (the initial 10-day period following PE diagnosis), unless contraindicated.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     If PE is subsequently excluded, anticoagulation can be discontinued. In patients with confirmed PE, anticoagulation should continue for at least 3 months.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Acute-phase parenteral anticoagulation (unfractionated heparin [UFH], low molecular weight heparin [LMWH], or fondaparinux) should overlap with the initiation of a vitamin K antagonist (VKA). Parenteral anticoagulation with UFH for a minimum of 5 days is the preferred acute-phase treatment for patients with high-risk PE (in whom primary re-perfusion [i.e., systemic thrombolytic therapy or embolectomy] is considered).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Parenteral UFH can be stopped once a therapeutic international normalised ratio (INR) of 2.0 to 3.0 has been established.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;UFH has a short half-life, is easy to monitor, and is readily reversed by protamine.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Two of the direct-acting oral anticoagulants, rivaroxaban and apixaban, may be prescribed without the need for pre-treatment with a parenteral anticoagulant. However, both dabigatran and edoxaban require lead-in therapy with a parenteral anticoagulant for 5 to 10 days. One meta-analysis found that direct-acting oral anticoagulants have similar efficacy to a heparin/VKA regimen, but with reduced risk of major bleeding (relative risk 0.61, 95% CI 0.21 to 0.68).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop170" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[170]</a> 
                     <span class="citationText" aria-hidden="true">van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014 Sep 18;124(12):1968-75.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.bloodjournal.org/content/124/12/1968.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24963045?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Furthermore, direct-acting oral anticoagulants do not require monitoring, have a rapid onset of action, and are short-acting. They do not interact with food, but they can interact with other pharmacotherapeutic agents. Dabigatran can be reversed with idarucizumab. Andexanet alfa is approved by the US Food and Drug Administration for the reversal of apixaban- and rivaroxaban-mediated anticoagulation in patients with life-threatening or uncontrolled bleeding. At present there is no approved reversal agent for edoxaban. 
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     European guidelines recommend UFH for obese patients, and for patients with severe renal impairment (creatinine clearance &lt;30 mL/minute).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;The American College of Chest Physicians recommends a VKA for patients with severe renal impairment.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     LMWH is the preferred agent for initial anticoagulation in patients with active cancer, or hepatic impairment and coagulopathy.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                     [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                     </a>
                     <span class="ccaTitle" aria-hidden="true">How do low‐molecular‐weight heparin (LMWH), vitamin K agonists (VKAs), and direct oral anticoagulants (DOACs) compare for treatment of venous thromboembolism (VTE) in people with cancer?</span>
                     <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2255/full</span>
                     <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with renal or hepatic impairment.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Fondaparinux carries a low risk of inducing heparin-induced thrombocytopenia (HIT) and appears to be effective for patients with suspected or confirmed HIT.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop171" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[171]</a> 
                     <span class="citationText" aria-hidden="true">Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924-9.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.bloodjournal.org/content/125/6/924.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25515959?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;It is contraindicated in patients with severe renal impairment.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Pregnancy
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     LMWH is recommended for women who are pregnant (weight-adjusted dose) or who may be pregnant.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop36" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[36]</a> 
                     <span class="citationText" aria-hidden="true">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-736S.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(12)60136-6/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     It does not cross the placenta, and routine monitoring is not generally required.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop172" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[172]</a> 
                     <span class="citationText" aria-hidden="true">Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top guideline No. 37a. Apr 2015 [internet publication].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
                     </span>
                     </span>
                     &nbsp;Other anticoagulants, including VKAs, may cross the placenta.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Primary re-perfusion in patients with shock or hypotension</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Systemic thrombolytic therapy is recommended in patients with haemodynamic compromise (shock or systolic BP &lt;90 mmHg), as this patient group has a high mortality rate.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop173" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[173]</a> 
                     <span class="citationText" aria-hidden="true">Hao Q, Dong BR, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004437.pub4/full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26419832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop174" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[174]</a> 
                     <span class="citationText" aria-hidden="true">Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18;311(23):2414-21.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://jamanetwork.com/journals/jama/fullarticle/1881311
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24938564?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Systemic thrombolytic therapy is associated with lower all-cause mortality than anticoagulation alone in patients with massive PE (acute PE with sustained hypotension [i.e., systolic BP &lt;90 mmHg for at least 15 minutes]).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop173" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[173]</a> 
                     <span class="citationText" aria-hidden="true">Hao Q, Dong BR, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004437.pub4/full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26419832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop174" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[174]</a> 
                     <span class="citationText" aria-hidden="true">Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18;311(23):2414-21.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://jamanetwork.com/journals/jama/fullarticle/1881311
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24938564?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop175" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[175]</a> 
                     <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/36/10/605/514452
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Ideally, PE should be confirmed by computed tomographic pulmonary angiography (CTPA) before thrombolytic therapy is administered.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;However, a negative ventilation-perfusion (V/Q) lung scan effectively excludes PE, and is a radiation- and medium-sparing procedure.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;If the patient is at risk of imminent cardiac arrest, treatment may be commenced on clinical grounds alone.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop176" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[176]</a> 
                     <span class="citationText" aria-hidden="true">British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003 Jun;58(6):470-83.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://thorax.bmj.com/content/58/6/470.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/12775856?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Systemic thrombolytic therapy induces prompt clot dissolution and improves right ventricular function, pulmonary blood flow, and lung perfusion.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop175" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[175]</a> 
                     <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/36/10/605/514452
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Thrombolysis plus heparin was associated with significantly reduced 30-day mortality compared with heparin alone (2.3% [24/1033] vs 3.9% [40/1024], respectively; pooled odds ratio [OR] 0.59, 95% CI 0.36 to 0.96, P = 0.03) in a meta-analysis of patients with acute PE.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop175" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[175]</a> 
                     <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/36/10/605/514452
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Thrombolysis is, however, associated with a significantly increased risk of major bleeding.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop173" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[173]</a> 
                     <span class="citationText" aria-hidden="true">Hao Q, Dong BR, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004437.pub4/full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26419832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop174" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[174]</a> 
                     <span class="citationText" aria-hidden="true">Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18;311(23):2414-21.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://jamanetwork.com/journals/jama/fullarticle/1881311
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24938564?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop175" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[175]</a> 
                     <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/36/10/605/514452
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;More patients receiving thrombolytic therapy plus heparin experienced a major bleeding episode compared with those taking an anticoagulant alone (9.9% [96/974] vs 3.6% [35/961], respectively; OR 2.91, 95% CI 1.95 to 4.36).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop175" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[175]</a> 
                     <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/36/10/605/514452
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;The reported incidence of intracranial or fatal haemorrhage was 1.7% in the thrombolysis group and 0.3% in the anticoagulant group.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop175" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[175]</a> 
                     <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/36/10/605/514452
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Absolute contraindications to thrombolysis include: haemorrhagic stroke or stroke of unknown origin at any time; ischaemic stroke in the preceding 6 months; central nervous system damage or neoplasms; recent major trauma/surgery/head injury (in the preceding 3 weeks); gastrointestinal bleeding within the last month; known bleeding risk.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop177" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[177]</a> 
                     <span class="citationText" aria-hidden="true">Van de Werf F, Ardissino D, Betriu A, et al; task force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003 Jan;24(1):28-66.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/24/1/28/562262
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/12559937?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Relative contraindications to thrombolysis include: transient ischaemic attack in the preceding 6 months; oral anticoagulant therapy; pregnancy, or within 1 week postnatally; traumatic resuscitation (in relation to this episode of PE); refractory hypertension (systolic BP &gt;180 mmHg); advanced liver disease; infective endocarditis; active peptic ulcer.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop177" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[177]</a> 
                     <span class="citationText" aria-hidden="true">Van de Werf F, Ardissino D, Betriu A, et al; task force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003 Jan;24(1):28-66.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/24/1/28/562262
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/12559937?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Thrombolytic therapy is not typically administered to haemodynamically stable patients with acute PE.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Primary re-perfusion thrombolytic therapy plus heparin in normotensive patients with intermediate-risk PE (acute right ventricular dysfunction and myocardial injury without overt haemodynamic compromise) prevented haemodynamic decompensation compared with heparin alone, but increased the risk of major haemorrhage and stroke.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop178" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[178]</a> 
                     <span class="citationText" aria-hidden="true">Meyer G, Vicaut E, Danays T, et al; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.nejm.org/doi/10.1056/NEJMoa1302097
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24716681?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Surgical embolectomy or catheter-directed therapy</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Systemic thrombolytic therapy increases bleeding risk, including that of intracranial bleeding.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Surgical pulmonary embolectomy and catheter-directed therapy have lower attendant bleeding risk than systemic therapy and may, therefore, be considered in high-risk patients unable to receive thrombolytic therapy because of bleeding risk, or when there is insufficient time for effective systemic thrombolytic therapy, or when such therapy has failed.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop179" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[179]</a> 
                     <span class="citationText" aria-hidden="true">Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000 Jan 24;160(2):181-8.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485206
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/10647756?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop180" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[180]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Surgical pulmonary embolectomy is recommended for patients in whom systemic thrombolytic therapy has failed or is absolutely contraindicated.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Mortality rates following pulmonary embolectomy range from 4% to 27%.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop181" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[181]</a> 
                     <span class="citationText" aria-hidden="true">Fukuda I, Daitoku K. Surgical embolectomy for acute pulmonary thromboembolism. Ann Vasc Dis. 2017 Jun 25;10(2):107-14.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579785/
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/29034035?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;In a small cohort of patients who underwent surgical pulmonary embolectomy for acute massive pulmonary thromboembolism, the 10-year survival rate was 84%.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop182" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[182]</a> 
                     <span class="citationText" aria-hidden="true">Fukuda I, Taniguchi S, Fukui K, et al. Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg. 2011 Mar;91(3):728-32.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.annalsthoracicsurgery.org/article/S0003-4975(10)02483-5/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21352987?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Catheter-directed therapy, which typically involves a combination of mechanical and pharmacotherapeutic thrombus fragmentation, may be considered for patients in whom full-dose systemic thrombolytic therapy has failed.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one third of full-dose systemic thrombolytic therapy) and is believed to reduce the risks of bleeding at remote sites (for example, intracranially or gastrointestinally).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;A meta-analysis of non-randomised trials of catheter-directed therapies reported a clinical success rate of 87% with an associated risk of major and minor complications of 2% and 8%, respectively.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop183" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[183]</a> 
                     <span class="citationText" aria-hidden="true">Kuo WT, Gould MK, Louie JD, at al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009 Nov;20(11):1431-40.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19875060?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Venous filters</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     An inferior vena cava (IVC) filter can be placed in patients with acute PE and an absolute contraindication to anticoagulant therapy, patients experiencing a major bleeding event during the acute phase, or patients with confirmed recurrent PE despite adequate anticoagulation.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Some centres insert IVC filters intraoperatively or immediately postoperatively in patients who undergo surgical pulmonary embolectomy.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop185" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[185]</a> 
                     <span class="citationText" aria-hidden="true">Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: Results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005 May;129(5):1018-23.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/15867775?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop186" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[186]</a> 
                     <span class="citationText" aria-hidden="true">Aklog L, Williams CS, Byrne JG, et al. Acute pulmonary embolectomy: a contemporary approach. Circulation. 2002 Mar 26;105(12):1416-9.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/105/12/1416.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/11914247?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop187" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[187]</a> 
                     <span class="citationText" aria-hidden="true">Greelish JP, Leacche M, Solenkova NS, et al. Improved midterm outcomes for type A (central) pulmonary emboli treated surgically. J Thorac Cardiovasc Surg. 2011 Dec;142(6):1423-9.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.jtcvs.org/article/S0022-5223(11)00280-7/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21481423?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Relative indications may include massive PE with residual deep venous thrombus in a patient at risk for further PE, free-floating iliofemoral or IVC thrombus, and severe cardiopulmonary disease and deep venous thrombosis (DVT) (e.g., cor pulmonale with pulmonary hypertension).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop188" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[188]</a> 
                     <span class="citationText" aria-hidden="true">American College of Radiology; Society of Interventional Radiology. ACR-SIR-SPR practice parameter for the performance of inferior vena cava (IVC) filter placement for the prevention of pulmonary embolism. Revised 2016 [internet publication].</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.acr.org/-/media/ACR/Files/Practice-Parameters/ivc-fliterplacement.pdf?la=en
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     IVC filter placement should take place as early as possible if it is the only treatment that can be initiated. There is little evidence available to suggest the ideal time for placement. However, the highest risk of dying is within the first 2 hours of presentation,
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop189" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[189]</a> 
                     <span class="citationText" aria-hidden="true">Tow DE, Wagner HN. Urokinase pulmonary embolism trial: Phase I results. JAMA. 1970 Dec 21;214(12):2163-72.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://jamanetwork.com/journals/jama/article-abstract/358702
                     </span>
                     </span>
                     which might indicate that this is a reasonable timeframe for filter placement. Observational studies suggest that insertion of a venous filter might reduce PE-related mortality rates in the acute phase but with an associated increase in the risk of filter-related venous thromboembolism (VTE).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop190" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[190]</a> 
                     <span class="citationText" aria-hidden="true">Stein PD, Matta F, Keyes DC, et al. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med. 2012 May;125(5):478-84.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.amjmed.com/article/S0002-9343(11)00481-5/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22310013?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                     <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Complications associated with permanent IVC filters are common, although they are rarely fatal.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                     <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                     </span>
                     </span>
                     Overall, early complications (including insertion-site thrombosis) occur in approximately 10% of patients. Late complications are more frequent and include recurrent DVT (approximately 20% of patients) and post-thrombotic syndrome (up to 40% of patients).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop192" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[192]</a> 
                     <span class="citationText" aria-hidden="true">Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev. 2013 Sep;27(5):225-41.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/23932118?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                     <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/112/3/416.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                     </span>
                     </span>
                     Occlusion of the IVC affects approximately 22% of patients at 5 years and 33% at 9 years, regardless of the use and duration of anticoagulation.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                     <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/112/3/416.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Post-filter anticoagulation should be considered on a case-by-case basis according to relative and absolute contraindications.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop194" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[194]</a> 
                     <span class="citationText" aria-hidden="true">Decousus H, Leizorovicz A, Parent F, et al; Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998 Feb 12;338(7):409-15.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://www.nejm.org/doi/10.1056/NEJM199802123380701
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/9459643?tool=bestpractice.com
                     </span>
                     </span>
                     Anticoagulation should be initiated if the contraindication resolves or if a risk/benefit analysis suggests this to be a reasonable course.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     When retrievable filters are used, they should be removed as soon as it is safe to use anticoagulants.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Prognostic stratification of patients with confirmed PE without shock or hypotension</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients with confirmed PE without shock or hypotension require further risk stratification, for example with the Pulmonary Embolism Severity Index (PESI) or the simplified Pulmonary Embolism Severity Index (sPESI).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.onlinejacc.org/content/67/8/976
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     PESI classifies patients with confirmed PE without shock or hypotension into 1 of 5 risk categories associated with increasing 30-day mortality. PESI risk category is derived from the sum of points for 11 clinical criteria; sPESI has only 6 criteria, and reports risk stratification dichotomously (low [0 points] or high [≥1 point(s)] risk of 30-day mortality).
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Studies indicate that PESI and sPESI predict short-term mortality with comparable accuracy, but the latter is easier to use.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop195" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[195]</a> 
                     <span class="citationText" aria-hidden="true">Vinson DR, Ballard DW, Mark DG, et al; MAPLE Investigators of the KP CREST Network. Risk stratifying emergency department patients with acute pulmonary embolism: does the simplified Pulmonary Embolism Severity Index perform as well as the original? Thromb Res. 2016 Dec;148:1-8.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/27764729?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop196" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[196]</a> 
                     <span class="citationText" aria-hidden="true">Zhou XY, Ben SQ, Chen HL, et al. The prognostic value of pulmonary embolism severity index in acute pulmonary embolism: a meta-analysis. Respir Res. 2012 Dec 4;13:111.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-13-111
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/23210843?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;One meta-analysis that evaluated the prognostic utility of PESI/sPESI for all-cause mortality reported pooled sensitivity and pooled specificity of 91% and 41%, respectively.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop196" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[196]</a> 
                     <span class="citationText" aria-hidden="true">Zhou XY, Ben SQ, Chen HL, et al. The prognostic value of pulmonary embolism severity index in acute pulmonary embolism: a meta-analysis. Respir Res. 2012 Dec 4;13:111.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-13-111
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/23210843?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Based upon social background and likely compliance with treatment, European Society of Cardiology guidelines suggest that low-risk patients (PESI class I or class II), and potentially those with a sPESI score of 0, can be considered for early discharge and outpatient management.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;PESI has been used to identify patients eligible for outpatient management in prospective studies.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop197" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[197]</a> 
                     <span class="citationText" aria-hidden="true">Roy PM, Moumneh T, Penaloza A, et al. Outpatient management of pulmonary embolism. Thromb Res. 2017 Jul;155:92-100.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/28525830?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop198" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[198]</a> 
                     <span class="citationText" aria-hidden="true">Bledsoe JR, Woller SC, Stevens SM, et al. Management of low-risk pulmonary embolism patients without hospitalization: the Low-Risk Pulmonary Embolism Prospective Management Study. Chest. 2018 Feb 2 [Epub ahead of print].</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/29410163?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     <span class="figureWrap">
                     <span class="figure">
                     <span class="figimage">
                     <img class="img-fluid" alt="com.bmj.content.model.Caption@256212e2" src="../images/116ROW-iline-4.gif" aria-describedby="img-116ROW-iline-4.gif" data-w="633">
                     </span>
                     <span class="figcaption">
                     <span id="img-116ROW-iline-4.gif">
                     <i class="remove">[Figure caption and citation for the preceding image starts]: </i>
                     <span class="caption">
                     PESI criteria and risk stratification
                     </span>
                     <span class="source">Created by BMJ Knowledge Centre</span>
                     <i class="remove"> [Citation ends].</i>
                     </span>
                     </span>
                     </span>
                     </span>
                     <span class="figureWrap">
                     <span class="figure">
                     <span class="figimage">
                     <img class="img-fluid" alt="com.bmj.content.model.Caption@716c0a5a" src="../images/116ROW-iline-5.gif" aria-describedby="img-116ROW-iline-5.gif" data-w="634">
                     </span>
                     <span class="figcaption">
                     <span id="img-116ROW-iline-5.gif">
                     <i class="remove">[Figure caption and citation for the preceding image starts]: </i>
                     <span class="caption">
                     sPESI criteria and risk stratification
                     </span>
                     <span class="source">Created by BMJ Knowledge Centre</span>
                     <i class="remove"> [Citation ends].</i>
                     </span>
                     </span>
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Rescue thrombolysis</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Right ventricular function assessed by echocardiography and cardiac troponin testing should be considered in patients with PESI risk stratification ≥III or sPESI ≥1.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;In patients with confirmed PE without shock or hypotension: right ventricular dysfunction is predictive of adverse outcome and enables further risk stratification;
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop149" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[149]</a> 
                     <span class="citationText" aria-hidden="true">Vanni S, Polidori G, Vergara R, et al. Prognostic value of ECG among patients with acute pulmonary embolism and normal blood pressure. Am J Med. 2009 Mar;122(3):257-64.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19272487?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop150" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[150]</a> 
                     <span class="citationText" aria-hidden="true">Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011 Apr 26;123(16):1788-830.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/123/16/1788.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21422387?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop151" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[151]</a> 
                     <span class="citationText" aria-hidden="true">Weekes AJ, Thacker G, Troha D, et al. Diagnostic accuracy of right ventricular dysfunction markers in normotensive emergency department patients with acute pulmonary embolism. Ann Emerg Med. 2016 Sep;68(3):277-91.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26973178?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;elevated troponin levels (troponin I or troponin T) are associated with increased risk for short-term mortality, PE-related mortality, and serious adverse events.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop199" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[199]</a> 
                     <span class="citationText" aria-hidden="true">Bajaj A, Saleeb M, Rathor P, et al. Prognostic value of troponins in acute nonmassive pulmonary embolism: a meta-analysis. Heart Lung. 2015 Jul-Aug;44(4):327-34.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25976228?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop200" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[200]</a> 
                     <span class="citationText" aria-hidden="true">Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007 Jul 24;116(4):427-33.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/116/4/427.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/17606843?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;In a prospective study of 526 normotensive patients with acute PE, high sensitivity troponin T ≥14 picograms/mL was associated with a prognostic sensitivity of 87% for adverse 30-day outcome.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop201" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[201]</a> 
                     <span class="citationText" aria-hidden="true">Lankeit M, Jiménez D, Kostrubiec M, et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011 Dec 13;124(24):2716-24.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/124/24/2716.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22082681?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Those with PESI risk stratification ≥III, or sPESI ≥1, with right ventricular dysfunction and a positive cardiac troponin I or T test belong to an intermediate high-risk group.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Rescue thrombolysis may be indicated in intermediate high-risk patients, and in patients with other clinical features of cardiopulmonary impairment (e.g., elevated heart rate, respiratory rate, jugular venous pressure) who have started anticoagulant therapy, and:
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Are deteriorating, but have not yet developed hypotension
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Are exhibiting signs of haemodynamic decompensation (e.g., systolic BP &lt;90 mmHg for at least 15 minutes, or drop of systolic BP by at least 40 mmHg for at least 15 minutes with signs of end organ hypoperfusion).
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Consideration of bleeding risk will inform choice of thrombolytic therapy.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Normotensive patients with PESI risk stratification ≥III, or sPESI ≥1, with normal echocardiogram and/or cardiac troponin test (e.g., high sensitivity troponin T &lt;14 picograms/mL) are considered to be intermediate-low risk.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Intermediate-low risk patients should be monitored if the cardiac troponin test is positive (even in the absence of right ventricular dysfunction); anticoagulant therapy should be maintained in all intermediate-low risk patients.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
               </section>
               <section>
                  <h3>Other prognostic indices</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The RIETE (Registro Informatizado de la Enfermedad TromboEmbolica venosa) and HESTIA criteria may be helpful in selecting patients (with venous thromboembolism at low risk of adverse clinical outcome) who could be managed as outpatients.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop202" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[202]</a> 
                     <span class="citationText" aria-hidden="true">Trujillo-Santos J, Lozano F, Lorente MA, et al; RIETE Investigators. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs. Am J Med. 2015 Jan;128(1):90.e9-15.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25242230?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop203" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[203]</a> 
                     <span class="citationText" aria-hidden="true">Zondag W, Vingerhoets LM, Durian MF, et al; Hestia Study Investigators. Hestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function. J Thromb Haemost. 2013 Apr;11(4):686-92.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://onlinelibrary.wiley.com/doi/full/10.1111/jth.12146
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/23336721?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop204" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[204]</a> 
                     <span class="citationText" aria-hidden="true">Weeda ER, Kohn CG, Peacock WF, et al. External validation of the Hestia criteria for identifying acute pulmonary embolism patients at low risk of early mortality. Clin Appl Thromb Hemost. 2017 Oct;23(7):769-74.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://journals.sagepub.com/doi/pdf/10.1177/1076029616651147
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/27225840?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Preliminary research has identified several biomarkers (e.g., brain natriuretic peptide [BNP], N-terminal proBNP [NT-proBNP], and heart-type fatty acid-binding protein [H-FABP]) that may help to predict clinical course in patients with confirmed PE without shock or hypotension.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop205" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[205]</a> 
                     <span class="citationText" aria-hidden="true">Jia D, Liu F, Zhang Q, et al. Rapid on-site evaluation of routine biochemical parameters to predict right ventricular dysfunction in and the prognosis of patients with acute pulmonary embolism upon admission to the emergency room. J Clin Lab Anal. 2018 May;32(4):e22362.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/29160572?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop206" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[206]</a> 
                     <span class="citationText" aria-hidden="true">Coutance G, Le Page O, Lo T, et al. Prognostic value of brain natriuretic peptide in acute pulmonary embolism. Crit Care. 2008;12(4):R109.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://ccforum.biomedcentral.com/articles/10.1186/cc6996
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/18721456?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop207" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[207]</a> 
                     <span class="citationText" aria-hidden="true">Bajaj A, Rathor P, Sehgal V, et al. Risk stratification in acute pulmonary embolism with heart-type fatty acid-binding protein: a meta-analysis. J Crit Care. 2015 Oct;30(5):1151.e1-7.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26111917?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;However, there is insufficient evidence to support their routine use in clinical practice.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop208" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[208]</a> 
                     <span class="citationText" aria-hidden="true">Bajaj A, Rathor P, Sehgal V, et al. Prognostic value of biomarkers in acute non-massive pulmonary embolism: a systematic review and meta-analysis. Lung. 2015 Oct;193(5):639-51.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26134045?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Ongoing anticoagulant therapy</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Recommendations for continuation of anticoagulant therapy vary by patient group. In patients who receive continued anticoagulation therapy, there is usually no need to change the initial oral anticoagulant.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     Continued anticoagulant therapy may be for a pre-determined timeframe (e.g., 3 months) or extended (with no scheduled stop date). 
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Evidence from studies of ≥6 months' duration suggests that there are no differences between direct-acting oral anticoagulants and conventional anticoagulation for the management of PE.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop209" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[209]</a> 
                     <span class="citationText" aria-hidden="true">Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev. 2015 Dec 4;(12):CD010957.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD010957.pub2/full
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26636644?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop210" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[210]</a> 
                     <span class="citationText" aria-hidden="true">Becattini C, Agnelli G. Risk stratification and management of acute pulmonary embolism. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):404-12.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://asheducationbook.hematologylibrary.org/content/2016/1/404.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/27913508?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                     [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                     </a>
                     <span class="ccaTitle" aria-hidden="true">How do oral direct thrombin inhibitors and oral factor Xa inhibitors compare with standard anticoagulation for the treatment of pulmonary embolism?</span>
                     <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1439/full</span>
                     <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                     </span>
                     &nbsp;In all patients who receive extended anticoagulant therapy, its continued use should be reassessed at periodic intervals (such as annually).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     When assessing bleeding risk, the following factors should be considered:
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     age &gt;65 years, previous bleeding, cancer, renal failure, liver failure, thrombocytopenia, previous stroke, diabetes mellitus, anaemia, antiplatelet therapy, poor anticoagulant control, comorbidity with reduced functional capacity, recent surgery, frequent falls, alcohol abuse, use of non-steroidal anti-inflammatory drugs. 
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients with none of these risk factors are considered low risk; one risk factor renders a patient moderate risk; and two or more risk factors renders a patient high risk.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Guidelines recommend the following oral anticoagulant treatment durations:
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           PE provoked by surgery: 3 months
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           PE provoked by a non-surgical transient risk factor: 3 months
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Unprovoked PE with low or moderate bleeding risk: extended anticoagulant therapy (i.e., no scheduled stop date) with periodic risk assessment to review risk-benefit ratio
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Unprovoked PE with high bleeding risk: 3 months.
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Active cancer
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     LMWH is preferred over a vitamin K antagonist (VKA), dabigatran, rivaroxaban, apixaban, or edoxaban for the treatment of PE in patients with active malignancy.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop211" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[211]</a> 
                     <span class="citationText" aria-hidden="true">Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20;33(6):654-6.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://ascopubs.org/doi/full/10.1200/JCO.2014.59.7351
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25605844?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                     [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                     </a>
                     <span class="ccaTitle" aria-hidden="true">How do low‐molecular‐weight heparin (LMWH), vitamin K agonists (VKAs), and direct oral anticoagulants (DOACs) compare for treatment of venous thromboembolism (VTE) in people with cancer?</span>
                     <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2255/full</span>
                     <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                     </span>
                     &nbsp;European guidelines recommend anticoagulant therapy for a period of 3 to 6 months;
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;the American College of Chest Physicians (ACCP) recommends extended anticoagulant therapy (i.e., no scheduled stop date).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;LMWH is more effective than a VKA in patients with cancer (moderate-quality evidence), is therapeutically reliable in patients for whom oral therapy may be inappropriate (e.g., vomiting), and is easier to adjust/withhold if thrombocytopenia develops or an invasive intervention is needed.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;Furthermore, patients with cancer treated with a VKA may be difficult to maintain within the therapeutic range, and experience substantial rates of recurrence.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Pregnancy
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           LMWH should be administered for at least 6 weeks postnatally in women at high risk of postnatal VTE, and for a minimum overall treatment duration of 3 months.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop212" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[212]</a> 
                           <span class="citationText" aria-hidden="true">Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top guideline No. 37a. Apr 2015 [internet publication].</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
                           </span>
                           </span>
                           &nbsp;Other anticoagulants, including VKAs, may cross the placenta.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                           <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           VKAs are an option for breastfeeding mothers.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                           <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://academic.oup.com/eurheartj/article/35/43/3033/503581
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                           </span>
                           </span>
                           &nbsp;
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Severe renal impairment
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           The ACCP recommends a VKA for patients with severe renal impairment (i.e., creatinine clearance &lt;30 mL/minute).
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                           <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                           </span>
                           </span>
                           &nbsp;Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with renal impairment. 
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Hepatic impairment and coagulopathy
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           ACCP guidelines recommend LMWH in this patient population.
                           <span class="reference"> 
                           <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                           <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                           </span>
                           </span>
                           Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with hepatic impairment. 
                        </p>
                     </li>
                  </ul>
               </section>
               <section>
                  <h3>Patients with recurrent VTE on anticoagulant therapy</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Recurrent VTE is unusual among patients receiving therapeutic-dose anticoagulant therapy.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;In addition to definitively establishing the presence of recurrent PE, consideration should be given to compliance with anticoagulant therapy or the presence of underlying malignancy.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     ACCP guidelines recommend a temporary switch to LMWH (for at least 1 month) for patients with recurrent PE who are thought to be compliant with a non-LMWH anticoagulant (or within the therapeutic range if receiving VKA therapy).
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                     &nbsp;An increased dose of LMWH (one quarter to one third) is appropriate for patients with recurrent PE who have been receiving LMWH.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Patients with recurrent VTE</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     For patients who are no longer receiving anticoagulant therapy and experience a second unprovoked PE, guidelines recommend the following anticoagulant treatment durations:
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                     <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://academic.oup.com/eurheartj/article/35/43/3033/503581
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                     <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Low or moderate bleeding risk: extended anticoagulant therapy with periodic reassessment to review risk-benefit ratio
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           High bleeding risk: 3 months.
                        </p>
                     </li>
                  </ul>
               </section>
            </div>
         </div>
         <div class="card-block disclaimer">
            <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
         </div>
      </main>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd><a href="https://bestpractice.bmj.com/login">Log in</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/registration">Create an account</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/" target="_blank">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/" target="_blank">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn"><small>ISSN 2515-9615</small></p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">
         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: Pulmonary embolism - Approach | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="Pulmonary embolism - Approach | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p><b>Phone:</b> +44 (0) 207 111 1105</p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/116/management-approach#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../js/common.js"></script>
      <script type="text/javascript" src="../js/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 116;
           var topicLang = "en-gb";
           var topicTitle = "Pulmonary embolism";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      <script type="text/javascript">
         _linkedin_data_partner_id = "103646";
      </script>
      <script type="text/javascript">
         (function()
         {var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);}
         )();
      </script>
      <script type="text/javascript" data-cfasync="false">
         (function(W,i,s,e,P,o,p){W['WisePopsObject']=P;W[P]=W[P]||function()
         { (W[P].q=W[P].q||[]).push(arguments)}
         ,W[P].l=1*new Date();o=i.createElement(s),
         p=i.getElementsByTagName(s)[0];o.async=1;o.src=e;p.parentNode.insertBefore(o,p)
         })(window,document,'script','//loader.wisepops.com/get-loader.js?v=1&site=qudyiEfMBd','wisepops');
         window.WisePopsLoaderCallback = function(wisepops) {
                         wisepops._storage.visits = wisepops._storage.visits.slice(0, 2);
                         wisepops._storage._saveVisits();
                       };
      </script>
      <noscript>
         <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=103646&fmt=gif" />
      </noscript>
      <!--[if lte IE 7]><script>var isIE7OrOlder = true; </script><![endif]-->   
      <!--[if lte IE 9]><script type="text/javascript" src="/gzip_e7393341757851d76c3264b590cf5143/js/browserupdate.js" ></script>
      <![endif]-->
      <script src="../js/adsct" type="text/javascript"></script><script type="text/javascript" id="createCookie">(function(){var b="bestpractice.bmj.com\/topics\/en-gb\/116\/management-approach",a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};a("RefTrack",b,2);a("RefTrackGroup","bestpractice.bmj.com",2)})();</script><script type="text/javascript" id="copyText">function getSelectionText(){var a="";window.getSelection?a=window.getSelection().toString():document.selection&&"Control"!=document.selection.type&&(a=document.selection.createRange().text);return a}document.addEventListener("copy",function(a){dataLayer.push({event:"textCopied",clipboardText:getSelectionText(),clipboardLength:getSelectionText().length})});</script>
      <script type="text/javascript" id="facebookPixel">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","414393182248444");fbq("track","PageView");</script>
      <noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=414393182248444&amp;ev=PageView&amp;noscript=1"></noscript>
      <button id="scrollTop" class="material-scrolltop" type="button"><span class="material-icons"></span></button><script src="../js/saved_resource" type="text/javascript"></script>
   </body>
</html>